Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
A Multicenter, Single Arm, Open Label Clinical Trial to Evaluate the Safety and Health-Related Quality of Life of Aflibercept in Patients With Metastatic Colorectal Cancer (mCRC) Previously Treated With an Oxaliplatin-Containing Regimen
Status: Enrolling
Updated:  2/28/2017
Clinical Research Facility
1184
mi
from 98109
Albuquerque, NM
Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
A Multicenter, Single Arm, Open Label Clinical Trial to Evaluate the Safety and Health-Related Quality of Life of Aflibercept in Patients With Metastatic Colorectal Cancer (mCRC) Previously Treated With an Oxaliplatin-Containing Regimen
Status: Enrolling
Updated: 2/28/2017
Clinical Research Facility
1184
mi
from 98109
Albuquerque, NM
Click here to add this to my saved trials
Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
A Multicenter, Single Arm, Open Label Clinical Trial to Evaluate the Safety and Health-Related Quality of Life of Aflibercept in Patients With Metastatic Colorectal Cancer (mCRC) Previously Treated With an Oxaliplatin-Containing Regimen
Status: Enrolling
Updated:  2/28/2017
Clinical Research Facility
1047
mi
from 98109
Farmington, NM
Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
A Multicenter, Single Arm, Open Label Clinical Trial to Evaluate the Safety and Health-Related Quality of Life of Aflibercept in Patients With Metastatic Colorectal Cancer (mCRC) Previously Treated With an Oxaliplatin-Containing Regimen
Status: Enrolling
Updated: 2/28/2017
Clinical Research Facility
1047
mi
from 98109
Farmington, NM
Click here to add this to my saved trials
Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
A Multicenter, Single Arm, Open Label Clinical Trial to Evaluate the Safety and Health-Related Quality of Life of Aflibercept in Patients With Metastatic Colorectal Cancer (mCRC) Previously Treated With an Oxaliplatin-Containing Regimen
Status: Enrolling
Updated:  2/28/2017
Clinical Research Facility
2414
mi
from 98109
Lake Success, NY
Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
A Multicenter, Single Arm, Open Label Clinical Trial to Evaluate the Safety and Health-Related Quality of Life of Aflibercept in Patients With Metastatic Colorectal Cancer (mCRC) Previously Treated With an Oxaliplatin-Containing Regimen
Status: Enrolling
Updated: 2/28/2017
Clinical Research Facility
2414
mi
from 98109
Lake Success, NY
Click here to add this to my saved trials
Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
A Multicenter, Single Arm, Open Label Clinical Trial to Evaluate the Safety and Health-Related Quality of Life of Aflibercept in Patients With Metastatic Colorectal Cancer (mCRC) Previously Treated With an Oxaliplatin-Containing Regimen
Status: Enrolling
Updated:  2/28/2017
Clinical Research Facility
1958
mi
from 98109
Middletown, OH
Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
A Multicenter, Single Arm, Open Label Clinical Trial to Evaluate the Safety and Health-Related Quality of Life of Aflibercept in Patients With Metastatic Colorectal Cancer (mCRC) Previously Treated With an Oxaliplatin-Containing Regimen
Status: Enrolling
Updated: 2/28/2017
Clinical Research Facility
1958
mi
from 98109
Middletown, OH
Click here to add this to my saved trials
Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
A Multicenter, Single Arm, Open Label Clinical Trial to Evaluate the Safety and Health-Related Quality of Life of Aflibercept in Patients With Metastatic Colorectal Cancer (mCRC) Previously Treated With an Oxaliplatin-Containing Regimen
Status: Enrolling
Updated:  2/28/2017
Investigational Site Number 056010
4921
mi
from 98109
Aalst,
Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
A Multicenter, Single Arm, Open Label Clinical Trial to Evaluate the Safety and Health-Related Quality of Life of Aflibercept in Patients With Metastatic Colorectal Cancer (mCRC) Previously Treated With an Oxaliplatin-Containing Regimen
Status: Enrolling
Updated: 2/28/2017
Investigational Site Number 056010
4921
mi
from 98109
Aalst,
Click here to add this to my saved trials
An Individualized Grief Intervention for Spouses of Cancer Patients After the Patient's Death
Enhancing End-of-Life and Bereavement Outcomes Among Cancer Caregivers: Individualized Dual Process Intervention for Bereaved Partners After Cancer Death
Status: Enrolling
Updated:  2/28/2017
University of Utah College of Nursing
702
mi
from 98109
Salt Lake City, UT
An Individualized Grief Intervention for Spouses of Cancer Patients After the Patient's Death
Enhancing End-of-Life and Bereavement Outcomes Among Cancer Caregivers: Individualized Dual Process Intervention for Bereaved Partners After Cancer Death
Status: Enrolling
Updated: 2/28/2017
University of Utah College of Nursing
702
mi
from 98109
Salt Lake City, UT
Click here to add this to my saved trials
Hospice and End-of-life Symptom Monitoring & Support Using an Automated System Designed for Family Caregivers
Enhancing End-of-Life and Bereavement Outcomes Among Cancer Caregivers: Symptom Care by Phone for Hospice Caregiver Support and Cancer Symptom Relief
Status: Enrolling
Updated:  2/28/2017
University of Utah College of Nursing
702
mi
from 98109
Salt Lake City, UT
Hospice and End-of-life Symptom Monitoring & Support Using an Automated System Designed for Family Caregivers
Enhancing End-of-Life and Bereavement Outcomes Among Cancer Caregivers: Symptom Care by Phone for Hospice Caregiver Support and Cancer Symptom Relief
Status: Enrolling
Updated: 2/28/2017
University of Utah College of Nursing
702
mi
from 98109
Salt Lake City, UT
Click here to add this to my saved trials
EPO906 in Carcinoid and Other Neuroendocrine Tumors
EPO906 Therapy in Patients With Metastatic Carcinoid Tumors and Other Neuroendocrine Tumors
Status: Enrolling
Updated:  2/28/2017
Northwestern University
1733
mi
from 98109
Chicago, IL
EPO906 in Carcinoid and Other Neuroendocrine Tumors
EPO906 Therapy in Patients With Metastatic Carcinoid Tumors and Other Neuroendocrine Tumors
Status: Enrolling
Updated: 2/28/2017
Northwestern University
1733
mi
from 98109
Chicago, IL
Click here to add this to my saved trials
EPO906 in Carcinoid and Other Neuroendocrine Tumors
EPO906 Therapy in Patients With Metastatic Carcinoid Tumors and Other Neuroendocrine Tumors
Status: Enrolling
Updated:  2/28/2017
University of Iowa Health Care
1557
mi
from 98109
Iowa City, IA
EPO906 in Carcinoid and Other Neuroendocrine Tumors
EPO906 Therapy in Patients With Metastatic Carcinoid Tumors and Other Neuroendocrine Tumors
Status: Enrolling
Updated: 2/28/2017
University of Iowa Health Care
1557
mi
from 98109
Iowa City, IA
Click here to add this to my saved trials
EPO906 in Carcinoid and Other Neuroendocrine Tumors
EPO906 Therapy in Patients With Metastatic Carcinoid Tumors and Other Neuroendocrine Tumors
Status: Enrolling
Updated:  2/28/2017
LSU HEALTH SCIENCES CENTER/ LSU SCHOOL OF MEDICINE Deptof LSU Health Sciences (2)
2099
mi
from 98109
New Orleans, LA
EPO906 in Carcinoid and Other Neuroendocrine Tumors
EPO906 Therapy in Patients With Metastatic Carcinoid Tumors and Other Neuroendocrine Tumors
Status: Enrolling
Updated: 2/28/2017
LSU HEALTH SCIENCES CENTER/ LSU SCHOOL OF MEDICINE Deptof LSU Health Sciences (2)
2099
mi
from 98109
New Orleans, LA
Click here to add this to my saved trials
EPO906 in Carcinoid and Other Neuroendocrine Tumors
EPO906 Therapy in Patients With Metastatic Carcinoid Tumors and Other Neuroendocrine Tumors
Status: Enrolling
Updated:  2/28/2017
Weill Medical College of Cornell University
2402
mi
from 98109
New York, NY
EPO906 in Carcinoid and Other Neuroendocrine Tumors
EPO906 Therapy in Patients With Metastatic Carcinoid Tumors and Other Neuroendocrine Tumors
Status: Enrolling
Updated: 2/28/2017
Weill Medical College of Cornell University
2402
mi
from 98109
New York, NY
Click here to add this to my saved trials
EPO906 in Carcinoid and Other Neuroendocrine Tumors
EPO906 Therapy in Patients With Metastatic Carcinoid Tumors and Other Neuroendocrine Tumors
Status: Enrolling
Updated:  2/28/2017
Oregon Health and Sciences University
145
mi
from 98109
Portland, OR
EPO906 in Carcinoid and Other Neuroendocrine Tumors
EPO906 Therapy in Patients With Metastatic Carcinoid Tumors and Other Neuroendocrine Tumors
Status: Enrolling
Updated: 2/28/2017
Oregon Health and Sciences University
145
mi
from 98109
Portland, OR
Click here to add this to my saved trials
Cancer Symptom Monitoring Telephone System With Nurse Practitioner (NP) Follow up
Telephone Linked Care: An IT Enabled Integrated System for Cancer Symptom Relief
Status: Enrolling
Updated:  2/28/2017
Vanderbilt-Ingram Cancer Center
1971
mi
from 98109
Nashville, TN
Cancer Symptom Monitoring Telephone System With Nurse Practitioner (NP) Follow up
Telephone Linked Care: An IT Enabled Integrated System for Cancer Symptom Relief
Status: Enrolling
Updated: 2/28/2017
Vanderbilt-Ingram Cancer Center
1971
mi
from 98109
Nashville, TN
Click here to add this to my saved trials
Cancer Symptom Monitoring Telephone System With Nurse Practitioner (NP) Follow up
Telephone Linked Care: An IT Enabled Integrated System for Cancer Symptom Relief
Status: Enrolling
Updated:  2/28/2017
University of Utah, Huntsman Cancer Institute
702
mi
from 98109
Salt Lake City, UT
Cancer Symptom Monitoring Telephone System With Nurse Practitioner (NP) Follow up
Telephone Linked Care: An IT Enabled Integrated System for Cancer Symptom Relief
Status: Enrolling
Updated: 2/28/2017
University of Utah, Huntsman Cancer Institute
702
mi
from 98109
Salt Lake City, UT
Click here to add this to my saved trials
Cancer & Chemotherapy Symptom Management Using an Automated Telephone Reporting System
Telephone Linked Care for Cancer Symptom Management
Status: Enrolling
Updated:  2/28/2017
Boston Med Ctr
2485
mi
from 98109
Boston, MA
Cancer & Chemotherapy Symptom Management Using an Automated Telephone Reporting System
Telephone Linked Care for Cancer Symptom Management
Status: Enrolling
Updated: 2/28/2017
Boston Med Ctr
2485
mi
from 98109
Boston, MA
Click here to add this to my saved trials
Cancer & Chemotherapy Symptom Management Using an Automated Telephone Reporting System
Telephone Linked Care for Cancer Symptom Management
Status: Enrolling
Updated:  2/28/2017
South Carolina Community Oncology Practice
2229
mi
from 98109
Greer, SC
Cancer & Chemotherapy Symptom Management Using an Automated Telephone Reporting System
Telephone Linked Care for Cancer Symptom Management
Status: Enrolling
Updated: 2/28/2017
South Carolina Community Oncology Practice
2229
mi
from 98109
Greer, SC
Click here to add this to my saved trials
Cancer & Chemotherapy Symptom Management Using an Automated Telephone Reporting System
Telephone Linked Care for Cancer Symptom Management
Status: Enrolling
Updated:  2/28/2017
University of Utah, Huntsman Cancer Institute
702
mi
from 98109
Salt Lake City, UT
Cancer & Chemotherapy Symptom Management Using an Automated Telephone Reporting System
Telephone Linked Care for Cancer Symptom Management
Status: Enrolling
Updated: 2/28/2017
University of Utah, Huntsman Cancer Institute
702
mi
from 98109
Salt Lake City, UT
Click here to add this to my saved trials
Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma
Analysis of the Expression of a Specific Set of Genes and Tumor Antigens in Patients With Non-small Cell Lung Cancer or Melanoma
Status: Enrolling
Updated:  3/2/2017
GSK Investigational Site
960
mi
from 98109
Los Angeles, CA
Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma
Analysis of the Expression of a Specific Set of Genes and Tumor Antigens in Patients With Non-small Cell Lung Cancer or Melanoma
Status: Enrolling
Updated: 3/2/2017
GSK Investigational Site
960
mi
from 98109
Los Angeles, CA
Click here to add this to my saved trials
Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma
Analysis of the Expression of a Specific Set of Genes and Tumor Antigens in Patients With Non-small Cell Lung Cancer or Melanoma
Status: Enrolling
Updated:  3/2/2017
GSK Investigational Site
1719
mi
from 98109
Park Ridge, IL
Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma
Analysis of the Expression of a Specific Set of Genes and Tumor Antigens in Patients With Non-small Cell Lung Cancer or Melanoma
Status: Enrolling
Updated: 3/2/2017
GSK Investigational Site
1719
mi
from 98109
Park Ridge, IL
Click here to add this to my saved trials
Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma
Analysis of the Expression of a Specific Set of Genes and Tumor Antigens in Patients With Non-small Cell Lung Cancer or Melanoma
Status: Enrolling
Updated:  3/2/2017
GSK Investigational Site
1718
mi
from 98109
St. Louis, MO
Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma
Analysis of the Expression of a Specific Set of Genes and Tumor Antigens in Patients With Non-small Cell Lung Cancer or Melanoma
Status: Enrolling
Updated: 3/2/2017
GSK Investigational Site
1718
mi
from 98109
St. Louis, MO
Click here to add this to my saved trials
Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma
Analysis of the Expression of a Specific Set of Genes and Tumor Antigens in Patients With Non-small Cell Lung Cancer or Melanoma
Status: Enrolling
Updated:  3/2/2017
GSK Investigational Site
706
mi
from 98109
Murray, UT
Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma
Analysis of the Expression of a Specific Set of Genes and Tumor Antigens in Patients With Non-small Cell Lung Cancer or Melanoma
Status: Enrolling
Updated: 3/2/2017
GSK Investigational Site
706
mi
from 98109
Murray, UT
Click here to add this to my saved trials
Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma
Analysis of the Expression of a Specific Set of Genes and Tumor Antigens in Patients With Non-small Cell Lung Cancer or Melanoma
Status: Enrolling
Updated:  3/2/2017
GSK Investigational Site
5152
mi
from 98109
Dijon,
Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma
Analysis of the Expression of a Specific Set of Genes and Tumor Antigens in Patients With Non-small Cell Lung Cancer or Melanoma
Status: Enrolling
Updated: 3/2/2017
GSK Investigational Site
5152
mi
from 98109
Dijon,
Click here to add this to my saved trials
A Study to Demonstrate the Benefit of a New Kind of Anti-cancer Treatment [PReferentially Expressed Antigen of MElanoma (PRAME) Immunotherapy] for Patients With Non-Small Cell Lung Cancer (NSCLC), After Removal of Their Tumor
GSK2302032A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/2/2017
GSK Investigational Site
2357
mi
from 98109
Newark, DE
A Study to Demonstrate the Benefit of a New Kind of Anti-cancer Treatment [PReferentially Expressed Antigen of MElanoma (PRAME) Immunotherapy] for Patients With Non-Small Cell Lung Cancer (NSCLC), After Removal of Their Tumor
GSK2302032A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/2/2017
GSK Investigational Site
2357
mi
from 98109
Newark, DE
Click here to add this to my saved trials
A Study to Demonstrate the Benefit of a New Kind of Anti-cancer Treatment [PReferentially Expressed Antigen of MElanoma (PRAME) Immunotherapy] for Patients With Non-Small Cell Lung Cancer (NSCLC), After Removal of Their Tumor
GSK2302032A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/2/2017
GSK Investigational Site
1705
mi
from 98109
Springfield, IL
A Study to Demonstrate the Benefit of a New Kind of Anti-cancer Treatment [PReferentially Expressed Antigen of MElanoma (PRAME) Immunotherapy] for Patients With Non-Small Cell Lung Cancer (NSCLC), After Removal of Their Tumor
GSK2302032A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/2/2017
GSK Investigational Site
1705
mi
from 98109
Springfield, IL
Click here to add this to my saved trials
A Study to Demonstrate the Benefit of a New Kind of Anti-cancer Treatment [PReferentially Expressed Antigen of MElanoma (PRAME) Immunotherapy] for Patients With Non-Small Cell Lung Cancer (NSCLC), After Removal of Their Tumor
GSK2302032A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/2/2017
GSK Investigational Site
1450
mi
from 98109
Rochester, MN
A Study to Demonstrate the Benefit of a New Kind of Anti-cancer Treatment [PReferentially Expressed Antigen of MElanoma (PRAME) Immunotherapy] for Patients With Non-Small Cell Lung Cancer (NSCLC), After Removal of Their Tumor
GSK2302032A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/2/2017
GSK Investigational Site
1450
mi
from 98109
Rochester, MN
Click here to add this to my saved trials
A Study to Demonstrate the Benefit of a New Kind of Anti-cancer Treatment [PReferentially Expressed Antigen of MElanoma (PRAME) Immunotherapy] for Patients With Non-Small Cell Lung Cancer (NSCLC), After Removal of Their Tumor
GSK2302032A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/2/2017
GSK Investigational Site
2409
mi
from 98109
Manchester, NJ
A Study to Demonstrate the Benefit of a New Kind of Anti-cancer Treatment [PReferentially Expressed Antigen of MElanoma (PRAME) Immunotherapy] for Patients With Non-Small Cell Lung Cancer (NSCLC), After Removal of Their Tumor
GSK2302032A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/2/2017
GSK Investigational Site
2409
mi
from 98109
Manchester, NJ
Click here to add this to my saved trials
A Study to Demonstrate the Benefit of a New Kind of Anti-cancer Treatment [PReferentially Expressed Antigen of MElanoma (PRAME) Immunotherapy] for Patients With Non-Small Cell Lung Cancer (NSCLC), After Removal of Their Tumor
GSK2302032A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/2/2017
GSK Investigational Site
2400
mi
from 98109
New York, NY
A Study to Demonstrate the Benefit of a New Kind of Anti-cancer Treatment [PReferentially Expressed Antigen of MElanoma (PRAME) Immunotherapy] for Patients With Non-Small Cell Lung Cancer (NSCLC), After Removal of Their Tumor
GSK2302032A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/2/2017
GSK Investigational Site
2400
mi
from 98109
New York, NY
Click here to add this to my saved trials
A Study to Demonstrate the Benefit of a New Kind of Anti-cancer Treatment [PReferentially Expressed Antigen of MElanoma (PRAME) Immunotherapy] for Patients With Non-Small Cell Lung Cancer (NSCLC), After Removal of Their Tumor
GSK2302032A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/2/2017
GSK Investigational Site
2371
mi
from 98109
Philadelphia, PA
A Study to Demonstrate the Benefit of a New Kind of Anti-cancer Treatment [PReferentially Expressed Antigen of MElanoma (PRAME) Immunotherapy] for Patients With Non-Small Cell Lung Cancer (NSCLC), After Removal of Their Tumor
GSK2302032A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/2/2017
GSK Investigational Site
2371
mi
from 98109
Philadelphia, PA
Click here to add this to my saved trials
A Study to Demonstrate the Benefit of a New Kind of Anti-cancer Treatment [PReferentially Expressed Antigen of MElanoma (PRAME) Immunotherapy] for Patients With Non-Small Cell Lung Cancer (NSCLC), After Removal of Their Tumor
GSK2302032A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/2/2017
GSK Investigational Site
26
mi
from 98109
Everett, WA
A Study to Demonstrate the Benefit of a New Kind of Anti-cancer Treatment [PReferentially Expressed Antigen of MElanoma (PRAME) Immunotherapy] for Patients With Non-Small Cell Lung Cancer (NSCLC), After Removal of Their Tumor
GSK2302032A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/2/2017
GSK Investigational Site
26
mi
from 98109
Everett, WA
Click here to add this to my saved trials
A Study to Demonstrate the Benefit of a New Kind of Anti-cancer Treatment [PReferentially Expressed Antigen of MElanoma (PRAME) Immunotherapy] for Patients With Non-Small Cell Lung Cancer (NSCLC), After Removal of Their Tumor
GSK2302032A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/2/2017
GSK Investigational Site
0
mi
from 98109
Seattle, WA
A Study to Demonstrate the Benefit of a New Kind of Anti-cancer Treatment [PReferentially Expressed Antigen of MElanoma (PRAME) Immunotherapy] for Patients With Non-Small Cell Lung Cancer (NSCLC), After Removal of Their Tumor
GSK2302032A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/2/2017
GSK Investigational Site
0
mi
from 98109
Seattle, WA
Click here to add this to my saved trials
A Study to Demonstrate the Benefit of a New Kind of Anti-cancer Treatment [PReferentially Expressed Antigen of MElanoma (PRAME) Immunotherapy] for Patients With Non-Small Cell Lung Cancer (NSCLC), After Removal of Their Tumor
GSK2302032A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/2/2017
GSK Investigational Site
4810
mi
from 98109
Tallinn,
A Study to Demonstrate the Benefit of a New Kind of Anti-cancer Treatment [PReferentially Expressed Antigen of MElanoma (PRAME) Immunotherapy] for Patients With Non-Small Cell Lung Cancer (NSCLC), After Removal of Their Tumor
GSK2302032A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/2/2017
GSK Investigational Site
4810
mi
from 98109
Tallinn,
Click here to add this to my saved trials
Green Tea Extract in Treating Patients With Low-Risk Prostate Cancer
Randomized Study of Sunphenon Decaffeinated Capsules in Men With Low-Risk Prostate Cancer on Active Surveillance
Status: Enrolling
Updated:  3/2/2017
University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center
2024
mi
from 98109
Cleveland, OH
Green Tea Extract in Treating Patients With Low-Risk Prostate Cancer
Randomized Study of Sunphenon Decaffeinated Capsules in Men With Low-Risk Prostate Cancer on Active Surveillance
Status: Enrolling
Updated: 3/2/2017
University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center
2024
mi
from 98109
Cleveland, OH
Click here to add this to my saved trials
A Pilot Trial to Determine the Extent of Inter- and Intra-Treatment Organ Motion Using Active Breathing Control Device (ABC) in Patients With Pancreatic Cancer
A Pilot Trial to Determine the Extent of Inter- and Intra-Treatment Organ Motion Using Active Breathing Control Device (ABC) in Patients With Pancreatic Cancer
Status: Enrolling
Updated:  3/2/2017
University of Michigan Cancer Center
1903
mi
from 98109
Ann Arbor, MI
A Pilot Trial to Determine the Extent of Inter- and Intra-Treatment Organ Motion Using Active Breathing Control Device (ABC) in Patients With Pancreatic Cancer
A Pilot Trial to Determine the Extent of Inter- and Intra-Treatment Organ Motion Using Active Breathing Control Device (ABC) in Patients With Pancreatic Cancer
Status: Enrolling
Updated: 3/2/2017
University of Michigan Cancer Center
1903
mi
from 98109
Ann Arbor, MI
Click here to add this to my saved trials
Association of Dihydropyrimidine Dehydrogenase (DPYD) Variants With Toxicity Related to Capecitabine
A Retrospective Analysis of the Association of Dihydropyrimidine Dehydrogenase (DPYD) Variants With Toxicity Related to Capecitabine
Status: Enrolling
Updated:  3/2/2017
University of Texas M.D. Anderson Cancer Center
1892
mi
from 98109
Houston, TX
Association of Dihydropyrimidine Dehydrogenase (DPYD) Variants With Toxicity Related to Capecitabine
A Retrospective Analysis of the Association of Dihydropyrimidine Dehydrogenase (DPYD) Variants With Toxicity Related to Capecitabine
Status: Enrolling
Updated: 3/2/2017
University of Texas M.D. Anderson Cancer Center
1892
mi
from 98109
Houston, TX
Click here to add this to my saved trials
Arsenic Trioxide in Combination With Cytarabine in Patients With High-risk MDS and Poor-prognosis AML
Phase I/II Study of Arsenic Trioxide in Combination With Cytosine Arabinoside in Patients With High-risk Myelodysplastic Syndrome and Poor-prognosis Acute Myelogenous Leukemia
Status: Enrolling
Updated:  3/2/2017
Weill Medcial College of Cornell University
2401
mi
from 98109
New York, NY
Arsenic Trioxide in Combination With Cytarabine in Patients With High-risk MDS and Poor-prognosis AML
Phase I/II Study of Arsenic Trioxide in Combination With Cytosine Arabinoside in Patients With High-risk Myelodysplastic Syndrome and Poor-prognosis Acute Myelogenous Leukemia
Status: Enrolling
Updated: 3/2/2017
Weill Medcial College of Cornell University
2401
mi
from 98109
New York, NY
Click here to add this to my saved trials
Study Comparing Radio Frequency Ablation Plus Chemotherapy and Chemotherapy Alone in Patients With Secondary Liver Metastases
A Prospective, Randomized, Active-Control, Multi-Center Study Assessing Overall Survival Using Chemotherapy With or Without Impedance-Based Radiofrequency Ablation for Subjects With Colorectal Cancer and Incurable Metastatic Liver Disease, Failing at Least First-Line Chemotherapy
Status: Enrolling
Updated:  3/2/2017
New York University
2402
mi
from 98109
New York, NY
Study Comparing Radio Frequency Ablation Plus Chemotherapy and Chemotherapy Alone in Patients With Secondary Liver Metastases
A Prospective, Randomized, Active-Control, Multi-Center Study Assessing Overall Survival Using Chemotherapy With or Without Impedance-Based Radiofrequency Ablation for Subjects With Colorectal Cancer and Incurable Metastatic Liver Disease, Failing at Least First-Line Chemotherapy
Status: Enrolling
Updated: 3/2/2017
New York University
2402
mi
from 98109
New York, NY
Click here to add this to my saved trials
Study Comparing Radio Frequency Ablation Plus Chemotherapy and Chemotherapy Alone in Patients With Secondary Liver Metastases
A Prospective, Randomized, Active-Control, Multi-Center Study Assessing Overall Survival Using Chemotherapy With or Without Impedance-Based Radiofrequency Ablation for Subjects With Colorectal Cancer and Incurable Metastatic Liver Disease, Failing at Least First-Line Chemotherapy
Status: Enrolling
Updated:  3/2/2017
Cleveland Clinic Foundation
2016
mi
from 98109
Cleveland, OH
Study Comparing Radio Frequency Ablation Plus Chemotherapy and Chemotherapy Alone in Patients With Secondary Liver Metastases
A Prospective, Randomized, Active-Control, Multi-Center Study Assessing Overall Survival Using Chemotherapy With or Without Impedance-Based Radiofrequency Ablation for Subjects With Colorectal Cancer and Incurable Metastatic Liver Disease, Failing at Least First-Line Chemotherapy
Status: Enrolling
Updated: 3/2/2017
Cleveland Clinic Foundation
2016
mi
from 98109
Cleveland, OH
Click here to add this to my saved trials
Dasatinib in Polycythemia Vera
A Phase II, Non-Randomized Study of the Use of Desatinib (Sprycel) in Treating Patients With Polycythemia Vera (PV) BMS Protocol Number: CA180-104
Status: Enrolling
Updated:  3/2/2017
Emory Winship Cancer Institute
2180
mi
from 98109
Atlanta, GA
Dasatinib in Polycythemia Vera
A Phase II, Non-Randomized Study of the Use of Desatinib (Sprycel) in Treating Patients With Polycythemia Vera (PV) BMS Protocol Number: CA180-104
Status: Enrolling
Updated: 3/2/2017
Emory Winship Cancer Institute
2180
mi
from 98109
Atlanta, GA
Click here to add this to my saved trials
Dasatinib in Polycythemia Vera
A Phase II, Non-Randomized Study of the Use of Desatinib (Sprycel) in Treating Patients With Polycythemia Vera (PV) BMS Protocol Number: CA180-104
Status: Enrolling
Updated:  3/2/2017
Hematology/Oncology Associates of Rockland
2389
mi
from 98109
New City, NY
Dasatinib in Polycythemia Vera
A Phase II, Non-Randomized Study of the Use of Desatinib (Sprycel) in Treating Patients With Polycythemia Vera (PV) BMS Protocol Number: CA180-104
Status: Enrolling
Updated: 3/2/2017
Hematology/Oncology Associates of Rockland
2389
mi
from 98109
New City, NY
Click here to add this to my saved trials
Dasatinib in Polycythemia Vera
A Phase II, Non-Randomized Study of the Use of Desatinib (Sprycel) in Treating Patients With Polycythemia Vera (PV) BMS Protocol Number: CA180-104
Status: Enrolling
Updated:  3/2/2017
Weill Cornell Medical College/New York Presbyterian Hospital
2402
mi
from 98109
New York, NY
Dasatinib in Polycythemia Vera
A Phase II, Non-Randomized Study of the Use of Desatinib (Sprycel) in Treating Patients With Polycythemia Vera (PV) BMS Protocol Number: CA180-104
Status: Enrolling
Updated: 3/2/2017
Weill Cornell Medical College/New York Presbyterian Hospital
2402
mi
from 98109
New York, NY
Click here to add this to my saved trials
Dasatinib in Polycythemia Vera
A Phase II, Non-Randomized Study of the Use of Desatinib (Sprycel) in Treating Patients With Polycythemia Vera (PV) BMS Protocol Number: CA180-104
Status: Enrolling
Updated:  3/2/2017
The Jones Clinic, PC
1877
mi
from 98109
Germantown, TN
Dasatinib in Polycythemia Vera
A Phase II, Non-Randomized Study of the Use of Desatinib (Sprycel) in Treating Patients With Polycythemia Vera (PV) BMS Protocol Number: CA180-104
Status: Enrolling
Updated: 3/2/2017
The Jones Clinic, PC
1877
mi
from 98109
Germantown, TN
Click here to add this to my saved trials
Evaluation of Food Effect on Pharmacokinetics of Vismodegib
Evaluation of Food Effect on Pharmacokinetics of GDC-0449, an Inhibitor of Hedgehog Signaling
Status: Enrolling
Updated:  3/6/2017
University of Chicago Comprehensive Cancer Center
1733
mi
from 98109
Chicago, IL
Evaluation of Food Effect on Pharmacokinetics of Vismodegib
Evaluation of Food Effect on Pharmacokinetics of GDC-0449, an Inhibitor of Hedgehog Signaling
Status: Enrolling
Updated: 3/6/2017
University of Chicago Comprehensive Cancer Center
1733
mi
from 98109
Chicago, IL
Click here to add this to my saved trials
Study of the Efficacy of Chloroquine in the Treatment of Ductal Carcinoma in Situ (The PINC Trial)
Preventing Invasive Breast Neoplasia With Chloroquine (PINC) Trial
Status: Enrolling
Updated:  3/7/2017
Medical Oncology and Hematology Associates of Northern Virginia
2313
mi
from 98109
Fairfax, VA
Study of the Efficacy of Chloroquine in the Treatment of Ductal Carcinoma in Situ (The PINC Trial)
Preventing Invasive Breast Neoplasia With Chloroquine (PINC) Trial
Status: Enrolling
Updated: 3/7/2017
Medical Oncology and Hematology Associates of Northern Virginia
2313
mi
from 98109
Fairfax, VA
Click here to add this to my saved trials
Study of the Efficacy of Chloroquine in the Treatment of Ductal Carcinoma in Situ (The PINC Trial)
Preventing Invasive Breast Neoplasia With Chloroquine (PINC) Trial
Status: Enrolling
Updated:  3/7/2017
Virginia Cancer Specialists, PC
2313
mi
from 98109
Fairfax, VA
Study of the Efficacy of Chloroquine in the Treatment of Ductal Carcinoma in Situ (The PINC Trial)
Preventing Invasive Breast Neoplasia With Chloroquine (PINC) Trial
Status: Enrolling
Updated: 3/7/2017
Virginia Cancer Specialists, PC
2313
mi
from 98109
Fairfax, VA
Click here to add this to my saved trials
Study of the Efficacy of Chloroquine in the Treatment of Ductal Carcinoma in Situ (The PINC Trial)
Preventing Invasive Breast Neoplasia With Chloroquine (PINC) Trial
Status: Enrolling
Updated:  3/7/2017
Virginia Surgery Associates
2306
mi
from 98109
Fairfax, VA
Study of the Efficacy of Chloroquine in the Treatment of Ductal Carcinoma in Situ (The PINC Trial)
Preventing Invasive Breast Neoplasia With Chloroquine (PINC) Trial
Status: Enrolling
Updated: 3/7/2017
Virginia Surgery Associates
2306
mi
from 98109
Fairfax, VA
Click here to add this to my saved trials
Study of the Efficacy of Chloroquine in the Treatment of Ductal Carcinoma in Situ (The PINC Trial)
Preventing Invasive Breast Neoplasia With Chloroquine (PINC) Trial
Status: Enrolling
Updated:  3/7/2017
Inova Fairfax Hospital
2314
mi
from 98109
Falls Church, VA
Study of the Efficacy of Chloroquine in the Treatment of Ductal Carcinoma in Situ (The PINC Trial)
Preventing Invasive Breast Neoplasia With Chloroquine (PINC) Trial
Status: Enrolling
Updated: 3/7/2017
Inova Fairfax Hospital
2314
mi
from 98109
Falls Church, VA
Click here to add this to my saved trials
Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
COMETI Phase 2: Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
Status: Enrolling
Updated:  3/7/2017
Arizona Oncology Associates, P.C.,
1116
mi
from 98109
Phoenix, AZ
Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
COMETI Phase 2: Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
Status: Enrolling
Updated: 3/7/2017
Arizona Oncology Associates, P.C.,
1116
mi
from 98109
Phoenix, AZ
Click here to add this to my saved trials
Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
COMETI Phase 2: Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
Status: Enrolling
Updated:  3/7/2017
Florida Cancer Specialists
2618
mi
from 98109
Ft. Myers, FL
Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
COMETI Phase 2: Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
Status: Enrolling
Updated: 3/7/2017
Florida Cancer Specialists
2618
mi
from 98109
Ft. Myers, FL
Click here to add this to my saved trials
Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
COMETI Phase 2: Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
Status: Enrolling
Updated:  3/7/2017
Florida Cancer Specialists, Site #179
mi
from 98109
St. Petersburg, FL
Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
COMETI Phase 2: Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
Status: Enrolling
Updated: 3/7/2017
Florida Cancer Specialists, Site #179
mi
from 98109
St. Petersburg, FL
Click here to add this to my saved trials
Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
COMETI Phase 2: Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
Status: Enrolling
Updated:  3/7/2017
Dana Faber Cancer Institute
2485
mi
from 98109
Boston, MA
Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
COMETI Phase 2: Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
Status: Enrolling
Updated: 3/7/2017
Dana Faber Cancer Institute
2485
mi
from 98109
Boston, MA
Click here to add this to my saved trials